**FOI Ref: 6098**

**Category(ies): Clinical - Drugs**

**Subject: Biologic Medications**

**Date Received: 15/11/2021**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Q1. How many patients were treated in October 2021 (or latest available month) by the dermatology department with the following drugs:* Abrocitinib (Cibinqo)
* Baricitinib (Olumiant)
* Bimekizumab (Bimzelx)
* Brodalumab (Kyntheum)
* Dupilumab (Dupixent)
* Ixekizumab (Taltz)
* Risankizumab (Skyrizi)
* Guselkumab (Tremfya)
* Secukinumab (Cosentyx)
* Tildrakizumab (Ilumetri)
* Tralokinumab (Adtralza)
* Ustekinumab (Stelara)
 | 0002223018200012 |
| Q2. How many patients were treated in October 2021 (or latest available month) by the rheumatology department with the following drugs:* Baricitinib (Olumiant)
* Filgotinib (Jyseleca)
* Guselkumab (Tremfya)
* Ixekizumab (Taltz)
* Secukinumab (Cosentyx)
* Tofacitinib (Xeljanz)
* Upadacitinib (Rinvoq)
* Ustekinumab (Stelara)
 | 140005201 |